Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C
The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
BACKGROUND: G12C is a mutation that occurs in approximately 3 to 4% of patients with metastatic colorectal cancer. Monotherapy with KRAS G12C inhibitors has yielded only modest efficacy. Combining the KRAS G12C inhibitor sotorasib with panitumumab, an epidermal growth factor receptor (EGFR) inhibitor, may be an effective strategy. METHODS: G12C who had not received previous treatment with a KRAS G12C inhibitor to receive sotorasib at a dose of 960 mg once daily plus panitumumab (53 patients), sotorasib at a dose of 240 mg once daily plus panitumumab (53 patients), or the investigator's choice of trifluridine-tipiracil or regorafenib (standard care; 54 patients). The primary end point was progression-free survival as assessed by blinded independent central review according to the Response Evaluation Criteria in Solid Tumors, version 1.1. Key secondary end points were overall survival and objective response. RESULTS: After a median follow-up of 7.8 months (range, 0.1 to 13.9), the median progression-free survival was 5.6 months (95% confidence interval [CI], 4.2 to 6.3) and 3.9 months (95% CI, 3.7 to 5.8) in the 960-mg sotorasib-panitumumab and 240-mg sotorasib-panitumumab groups, respectively, as compared with 2.2 months (95% CI, 1.9 to 3.9) in the standard-care group. The hazard ratio for disease progression or death in the 960-mg sotorasib-panitumumab group as compared with the standard-care group was 0.49 (95% CI, 0.30 to 0.80; P = 0.006), and the hazard ratio in the 240-mg sotorasib-panitumumab group was 0.58 (95% CI, 0.36 to 0.93; P = 0.03). Overall survival data are maturing. The objective response was 26.4% (95% CI, 15.3 to 40.3), 5.7% (95% CI, 1.2 to 15.7), and 0% (95% CI, 0.0 to 6.6) in the 960-mg sotorasib-panitumumab, 240-mg sotorasib-panitumumab, and standard-care groups, respectively. Treatment-related adverse events of grade 3 or higher occurred in 35.8%, 30.2%, and 43.1% of patients, respectively. Skin-related toxic effects and hypomagnesemia were the most common adverse events observed with sotorasib-panitumumab. CONCLUSIONS: In this phase 3 trial of a KRAS G12C inhibitor plus an EGFR inhibitor in patients with chemorefractory metastatic colorectal cancer, both doses of sotorasib in combination with panitumumab resulted in longer progression-free survival than standard treatment. Toxic effects were as expected for either agent alone and resulted in few discontinuations of treatment. (Funded by Amgen; CodeBreaK 300 ClinicalTrials.gov number, NCT05198934.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Interestingly, KRAS G12C (glycine to cysteine) can be targeted using the covalent inhibitors, such as sotorasib, in combination with EGFR antagonists, such as panitumumab [75].”
From Overcoming Resistance to Anti-EGFR Therapies: Mechanisms of Cetuximab and Panitumumab Resistance and Emerging Combination Strategies (2026) · cites this paper as [75]
In the citing paper
“While KRAS and EGFR dual targeting holds promise in KRAS-mutant CRC, responses are often short-lived; most patients relapse within months due to acquired resistance.”
From Paneth-like transition drives resistance to dual targeting of KRAS and EGFR in colorectal cancer (2026) · cites this paper as [6]
In the citing paper
“While dual KRAS and epidermal growth factor receptor (EGFR) inhibition shows promise in treating KRAS-mutant colorectal cancer (CRC), resistance remains a major challenge.”
From Paneth-like transition drives resistance to dual targeting of KRAS and EGFR in colorectal cancer (2026) · cites this paper as [6]
In the citing paper
“the phase 3 CodeBreaK 300 trial comparing sotorasib at two doses (960 mg or 240 mg) plus panitumumab with investigator's choice of trifluridine/tipiracil or regorafenib in patients with chemotherapy-refractory KRAS G12C-mutated metastatic colorectal cancer was ongoing, and has shown improved progression-free survival with this combination strategy at both the doses tested. 19”
From Sotorasib with panitumumab in chemotherapy-refractory KRASG12C-mutated colorectal cancer: a phase 1b trial (2024) · cites this paper as [19]
In the citing paper
“Clinical studies of other KRAS G12C inhibitors, such as sotorasib and adagrasib, support this hypothesis, with higher response rates observed when used in combination with an EGFR inhibitor compared to when used as single-agent treatment in patients with CRC16–20.”
From Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial (2024) · cites this paper as [17]
23 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207
Grothey, A., Cutsem, E. V., Sobrero, A., Siena, S., Falcone, A., Ychou, M., Humblet, Y., Bouché, O., Mineur, L., Barone, C., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61900-x · Cited by 2,895
The Clinical KRAS(G12C) Inhibitor AMG 510 Drives Anti-Tumour Immunity
Canon, J., Rex, K., Saiki, A. Y., Mohr, C., Cooke, K., Bagal, D., Gaida, K., Holt, T., Knutson, C. G., Koppada, N., et al. (2019) · Nature · doi:10.1038/s41586-019-1694-1 · Cited by 2,277
Self-citationSotorasib for Lung Cancers with KRAS p.G12C Mutation
Skoulidis, F., Li, B. T., Dy, G. K., Price, T. J., Falchook, G. S., Wolf, J., Italiano, A., Schuler, M., Borghaei, H., Barlesi, F., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2103695 · Cited by 1,849
Self-citationRandomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
Mayer, R. J., Van Cutsem, E., Falcone, A., Yoshino, T., Garcia-Carbonero, R., Mizunuma, N., Yamazaki, K., Shimada, Y., Tabernero, J., Komatsu, Y., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414325 · Cited by 1,431
Acquired Resistance to KRAS G12C Inhibition in Cancer
Awad, M. M., Liu, S., Rybkin, I. I., Arbour, K. C., Dilly, J., Zhu, V. W., Johnson, M. L., Heist, R. S., Patil, T., Riely, G. J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2105281 · Cited by 1,247
Adagrasib in Non–Small-Cell Lung Cancer Harboring a KRAS G12C Mutation
Jänne, P. A., Riely, G. J., Gadgeel, S. M., Heist, R. S., Ou, S.-H. I., Pacheco, J. M., Johnson, M. L., Sabari, J. K., Leventakos, K., Yau, E., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2204619 · Cited by 1,061
Tabernero, J., Grothey, A., Van Cutsem, E., Yaeger, R., Wasan, H., Yoshino, T., Desai, J., Ciardiello, F., Loupakis, F., Hong, Y. S., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.02088 · Cited by 569
Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C
Yaeger, R., Weiss, J., Pelster, M. S., Spira, A. I., Barve, M., Ou, S.-H. I., Leal, T. A., Bekaii-Saab, T. S., Paweletz, C. P., Heavey, G. A., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2212419 · Cited by 527
Cited by
Items 201–300 of 381
Concurrent genetic and non-genetic resistance mechanisms to KRAS inhibition in colorectal cancer
Alonso, S., Chu, K., Granowsky, E., Saraiba-Rabanales, V., Parsons, M. J., Gunasinghe, H. I., Shia, J., Yaeger, R., & Dow, L. E. (2026) · Cancer Cell · doi:10.1016/j.ccell.2026.04.009 · Cited by 13
Xue, S., Xu, H., Ma, J., Wang, Y., Lu, W., Cui, J., & Wang, L. (2026) · Cancer Letters · doi:10.1016/j.canlet.2026.218684 · Cited by 2
Mahadevan, K. K., Maldonado, A. S., Li, B., Bickert, A. A., Perdyan, A., Kumbhar, S. V., Piya, S., Sockwell, A. M., Morse, S. J., Arian, K. A., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-75960-3 · Cited by 12
Mutant RAS-driven Secretome Causes Skeletal Muscle Defects in Breast Cancer
Wang, R., Khatpe, A. S., Kumar, B., Mang, H. E., Batic, K., Adebayo, A. K., & Nakshatri, H. (2024) · Cancer Research Communications · doi:10.1158/2767-9764.crc-24-0045 · Cited by 3
Mutant KRAS inhibitors enter the scene of precision therapeutics for pancreatic cancer
Pollin, G., Lomberk, G. A., Mathison, A., Zimmermann, M. T., & Urrutia, R. A. (2024) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-24-326 · Cited by 2
“This study found that the combination treatment resulted in longer progression-free survival compared to standard treatment (19).”
Ekmekçiu, I., Zucha, D. M., Christmann, J., Wisser, S., Heuer, V., Sargin, B., Hollerbach, S. H., Lamberti, C., Müller, L., Lugnier, C., et al. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1434791 · Cited by 2
“Compounds like sotorasib and adagrasib, which selectively inhibit the KRAS p.G12C mutation, are being tested in combination with anti-EGFR antibodies in the context of metastatic CC and have delivered promising results (9, 10).”
Metastatic colon cancer: clinical practice guideline update in 2024
Fedyanin, M. Y., Gladkov, O. A., Gordeyev, S. S., Карачун, А. М., Козлов, Н. А., Mamedli, Z. Z., Rykov, I. V., Tryakin, A. A., Цуканов, А. С., & Черных, М. В. (2024) · Surgery and Oncology · doi:10.17650/2949-5857-2024-14-4-31-42 · Cited by 3
Doğan, H. T., Doğan, M., Kahraman, S., Çanakçı, D., Şendur, M. A. N., Tahtacı, M., & Erdoğan, F. (2025) · Diagnostics · doi:10.3390/diagnostics15020184 · Cited by 3
“In stage IV patients, progression-free survival (PFS) was defined as the time to first progression or deaths related to progression [24,25].”
Arter, Z., Lee, A. T., Nagasaka, M., & Ou, S. I. (2025) · Cancer Medicine · doi:10.1002/cam4.70665 · Cited by 7
Ma, Y., Sun, Y., Tu, Q., Lin, F., Feng, M., Chen, Q., Fu, T., Yang, L., Lai, X., Yang, M., et al. (2025) · Chemical Biology & Drug Design · doi:10.1111/cbdd.70125 · Cited by 3
Wang, W., Alley, A., Sun, N., Tadesse, M., Wang, X., & Zhang, R. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1663766 · Cited by 7
Pathak, P., Weekes, C. D., & Wo, J. Y.-L. (2024) · The Lancet Oncology · doi:10.1016/s1470-2045(24)00290-0 · Cited by 2
Henrykowska, G., Bartusik-Aebisher, D., Dynarowicz, K., Ramesh, T. S., Smolak, B., & Aebisher, D. (2026) · Pharmaceuticals · doi:10.3390/ph19071041 · Cited by 1
“Interestingly, KRAS G12C (glycine to cysteine) can be targeted using the covalent inhibitors, such as sotorasib, in combination with EGFR antagonists, such as panitumumab [75].”
Systemic Therapy for Metastatic Colon Cancer: New Frontiers
Pumpalova, Y. S. (2024) · Clinics in Colon and Rectal Surgery · doi:10.1055/s-0044-1787826 · Cited by 2
“39 The KRYSTAL-1 trial was a nonrandomized phase 1b/2 trial evaluating the activity of adagrasib monotherapy and adagrasib/cetuximab combination therapy.”
BackgroundTamayo, N. A., Wurz, R. P., & Lanman, B. A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-21861-3.00001-2 · Cited by 1
Hussung, S., Akhoundova, D., Pistoni, C., Lenggenhager, D. M., Töpfer, A., Pauli, C., Pestalozzi, B., Britschgi, C., Zoche, M., Rechsteiner, M., et al. (2025) · ESMO Gastrointestinal Oncology · doi:10.1016/j.esmogo.2025.100134 · Cited by 2
The emerging role of Sotorasib plus Panitumumab combination therapy in colorectal cancer treatment
Kokori, E., Olatunji, G. D., Ogieuhi, I. J., Ajayi, Y. I., Akinmoju, O. D., Akinboade, A., Irumudomon, J. G., Omoworare, O. T., Ezeano, C., Adebayo, Y. A., et al. (2025) · International Journal of Clinical Oncology · doi:10.1007/s10147-025-02736-y · Cited by 2
Challenges and opportunities of emerging mechanisms of resistance to KRASG12C inhibitors
Cecchini, M., & LoRusso, P. M. (2025) · Annals of Oncology · doi:10.1016/j.annonc.2025.03.009 · Cited by 1
Chaperone directed heterobifunctional molecules circumvent KRASG12C inhibitor resistance
Pulido, I., Luan, Q., Pastor-Puente, S., Gunder, L. C., Wang, Y., Ying, C., Li, J., Sun, Y., Dai, Y., Ascoli, C., et al. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217691 · Cited by 1
Clinical and prognostic characteristics of metastatic colorectal cancer with minor RAS mutations
Kojitani, Y., Sakai, D., Ogata, T., Amano, Y., Mori, R., Kitakaze, M., Sueda, T., Otsuka, T., Nishio, M., Ishihara, M., et al. (2025) · Oncology Letters · doi:10.3892/ol.2025.15123 · Cited by 1
“However, recent advancements have led to the FDA approval of targeted therapies such as adagrasib plus cetuximab and sotorasib plus panitumumab for KRAS G12C mutations, expanding treatment options (28,29).”
Ismail, A., Boateng, W. K. B., Alnakeb, A., Botros, Y., & Cruz, A. L. (2025) · Case Reports in Gastrointestinal Medicine · doi:10.1155/crgm/8864636 · Cited by 2
“KRAS G12C inhibitors (e.g., Sotorasib or Adagrasib) in combination with EGFR inhibitors (e.g., Cetuximab or Panitumumab) are studied and being used in the treatment of mCRC with KRAS G12C mutations [18, 19].”
Co-targeting KRASG12D and the HER family is efficacious in colorectal cancer
Kilroy, M. K., Wischmeier, C., Park, B. S., Choi, D., Feroz, W., Mishra, R., & Garrett, J. T. (2025) · Carcinogenesis · doi:10.1093/carcin/bgaf036 · Cited by 3
Antibody treatments for digestive cancers: Past, present, and future
Dadi, I., Mazard, T., Schmitt, L.-M., Chastel, T., Turtoï, A., Poul, M., & Pattingre, S. (2025) · Seminars in Oncology · doi:10.1016/j.seminoncol.2025.152369 · Cited by 1
FOXP2/SOS1/AKT negative feedback loop inhibits cell proliferation in KRAS-mutant colorectal cancer
Liu, J., Wang, Y., Liu, Y., Mei, H., Zhang, Q., Gao, Z., Zhang, M., Yang, Z., Wang, H., & Qiu, M. (2025) · APOPTOSIS · doi:10.1007/s10495-025-02154-5 · Cited by 4
Bai, M., Lu, Y., Shen, L., Yin, X., Gao, S., Xia, B., Fu, Z., Zhang, Z., Xie, L., & Ba, Y. (2025) · Cancer · doi:10.1002/cncr.70046 · Cited by 3
“23,34 Hypomagnesemia is the main renal adverse event of anti - EGFR mAbs.”
A Comprehensive Molecular and Clinical Study of Patients with Young-Onset Colorectal Cancer
Nasrollahi, E., Wang, S., Yanes, R. B., Gomez, C. G., Magge, T., Overacre-Delgoffe, A. E., Hsieh, R. W., McFarquhar, A., Tatsuoka, C. M., Singhi, A. D., et al. (2025) · Cancers · doi:10.3390/cancers17172763 · Cited by 2
“Recently, drug discovery research resulted in practice-changing developments in KRAS targeting with novel covalent molecules that inhibit KRAS G12C oncoprotein [33–35].”
Davoudi, Z., Dexheimer, T. S., Coussens, N. P., Silvers, T. E., Fox, R. G., Kemp, S. B., Juneja, P., Morris, J., Hollingshead, M. G., Takebe, N., et al. (2025) · Cancer Research Communications · doi:10.1158/2767-9764.crc-24-0582 · Cited by 2
The importance and utility of post market drug safety monitoring in cancer therapy
Levêque, D. (2025) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2025.2575099 · Cited by 4
“The median progression free survival (primary end point) was slightly superior with the 960 mg dosage (5.6 months versus 3.9 months with 240 mg) but again with similar drug exposures [87].”
InfluentialUnlocking RAS: Finding the Right Combination Is the Key
Papke, B., & Der, C. J. (2025) · United European Gastroenterology Journal · doi:10.1002/ueg2.70138 · Cited by 1
Terasaki, F., Kumagai, S., Fukuda, A., Tanaka, Y., Irie, T., Ito, S., Yamada, M., Onoe, S., Mizuno, T., Kokuryo, T., et al. (2025) · International Immunology · doi:10.1093/intimm/dxaf065 · Cited by 3
KRAS G12A Identifies a High-Risk Subset in Resected Stage II–III Colorectal Cancer
Momma, T., Okayama, H., Hayashishita, S., Yamaguchi, D., Fujii, A., Katagata, M., Matsumoto, T., Ujiie, D., Chida, S., Saze, Z., et al. (2025) · Cancers · doi:10.3390/cancers17223599 · Cited by 1
“KRAS G12C has also been linked to unfavorable OS and progression-free survival (PFS), with implications for targeted therapeutic development for mCRC harboring this variant [5,7,12,15,18,19].”
Wu, R., Liu, Y., Fu, J., Zhou, T., Hu, R., Yang, B., He, Q., Yuan, T., & Zhu, H. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.108027 · Cited by 1
Modern Approaches to Anti-EGFR Therapy
Владимировна, Д. Е., Nadyrova, A. I., Luginskaya, S., Kosnyrev, A. S., Владимировна, У. В., & Ilinskaya, O. N. (2025) · Molecular Biology · doi:10.1134/s0026893325700347 · Cited by 1
Targeting RAS for Cancer Treatment: What a Long, Strange Trip It's Been
Cox, A. D., & Der, C. J. (2025) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-071024-082459 · Cited by 1
Unlocking New Treatment Possibilities for Metastatic Endometrial Cancer With KRAS G12C Mutation
Antonios, B., Abioye, O. F., Park, S. J., & Finley, G. G. (2025) · Case Reports in Oncological Medicine · doi:10.1155/crom/7966703 · Cited by 1
New Frontiers in the Treatment of Rectal Cancer
Yeh, C., Wheless, M. C., Ciombor, K. K., & Cercek, A. (2025) · Annual Review of Medicine · doi:10.1146/annurev-med-050124-085830 · Cited by 5
Guo, L., Wang, Y., Yang, C., Qi, W., & Wang, S. (2025) · Scientific Reports · doi:10.1038/s41598-025-26317-1 · Cited by 1
“However, KRAS G12C inhibitors combined with EGFR blockade have demonstrated meaningful efficacy in patients who received prior treatments 21 .”
The evolving landscape of RAS-targeted therapies
Misale, S. (2025) · Nature Cancer · doi:10.1038/s43018-025-01077-z · Cited by 1
An overview of KRAS-targeting therapies for colorectal cancer in phase I and II development
Chamseddine, S., Azmi, A. S., & Saif, M. W. (2025) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2025.2611395 · Cited by 2
“Clinically, this strategy is exemplified by the CodeBreaK 300 trial, which compares sotorasib plus panitumumab to standard therapy in KRAS G12C – mutant CRC [77].”
Accessibility of Somatic Genetic Testing for Cancer Treatment Decisions
Klavans, M. R., Musa, F., & Huang, M. (2026) · Annual Review of Medicine · doi:10.1146/annurev-med-050124-082437 · Cited by 1
KRAS , NRAS and BRAF Mutational Landscape in Serbian Early-Onset Colorectal Cancer Patients
Despotović, J., Nikolić, N., Babič, T., Ugrin, M., Rom, A. D., Damjanović, A., Nikolic, A., & Dragičević, S. (2026) · Cancer Control · doi:10.1177/10732748261426049 · Cited by 1
Boby, J. M., Ilerhunmwuwa, N. P., Benny, J. M., Peniche, P. Z., Baytar, D. K., & Sahin, I. H. (2026) · Cancer Investigation · doi:10.1080/07357907.2026.2636581 · Cited by 1
“…dose level of certain KRAS G12C inhibitors also appears to play a role in determining the treatment response, as demonstrated by the CodeBreaK 300 trial, where the ORR rose from 5.7% to 26.4% when the daily dose was raised from 240 mg to 960 mg, suggesting dose-dependent efficacy of sotorasib (28).”
InfluentialToyokawa, E., Ooki, A., Shinozaki, E., Yoshikawa, K., Suzuki, K., Shiozawa, M., Maeda, S., Yamaguchi, K., & Osumi, H. (2026) · Biomolecules · doi:10.3390/biom16040543 · Cited by 1
“The phase III CodeBreaK 300 trial demonstrated that sotorasib plus panitumumab significantly improved PFS compared with standard salvage therapies (mPFS: 5.6 vs. 2.0 months; HR: 0.48) [120].”
InfluentialThe impact of K-Ras Gly12 mutants on homeostasis and tumorigenesis in the colonic epithelium
Yang, M. H., Sheth, S., Shui, B., Grabski, I. N., Park, S. S., Galán‐Cobo, A., Irizarry, R. A., Heymach, J. V., Dow, L. E., & Haigis, K. M. (2026) · Oncogene · doi:10.1038/s41388-026-03771-3 · Cited by 1
“Notably, this mutant-speci fi c survival phenotype differs from A.”
Pancreatic cancer: emerging small molecule pharmacotherapies
Pokora, B., Pokora, K., & Fichna, J. (2026) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2026.2657995 · Cited by 1
Fan, J., Gu, J. F., Jia, B., Li, J., Qin, X., Wang, X., Xu, J., Xu, R., Ye, Y., 张苏展, et al. (2026) · Clinical Cancer Bulletin · doi:10.1007/s44272-026-00062-6 · Cited by 3
“Furthermore, testing for specific mutations such as KRAS G12C or G12D may assist in selecting novel targeted agents in post-progression treatment [42, 43].”
Harmych, S. J., Joshi, N., Tanaka, H., Bogatcheva, G. T., Ramirez, M. A., Graves‐Deal, R., Tydings, C. W., Elia, M. T., Mueller, H. R. L., Silvestri, I. M., et al. (2026) · Cancer Letters · doi:10.1016/j.canlet.2026.218607 · Cited by 1
Leto, S. M., Sassi, F. P., Zanella, E. R., Vurchio, V., Cottino, F., Ferri, M., Damico, A., Grassi, E., Bertotti, A., & Trusolino, L. (2026) · Cell Death and Disease · doi:10.1038/s41419-026-08900-0 · Cited by 1
ADCs for colorectal carcinoma: decoding clinical evidence for molecular design innovation
Wu, X., Du, F., Liu, Z., Zhang, B. H., Tong, J., Liu, Y., & Xia, T. (2026) · SLAS DISCOVERY · doi:10.1016/j.slasd.2026.100320 · Cited by 1
Killock, D. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00835-1 · Cited by 1
Palliative Systemtherapie des metastasierten Rektumkarzinoms
Seufferlein, T. T. W., & Ettrich, T. J. (2024) · Zentralblatt für Chirurgie - Zeitschrift für Allgemeine Viszeral- Thorax- und Gefäßchirurgie · doi:10.1055/a-2241-0128 · Cited by 1
Bedau, T., Heydt, C., Siebolts, U., Zander, T., Kraemer, M., Loeser, H., Buettner, R., & Quaas, A. (2024) · Diagnostic Pathology · doi:10.1186/s13000-024-01478-1 · Cited by 1
“In CRC, these inhibitors have shown promising results in combination with epidermal growth factor receptor (EGFR) inhibition (Cetuximab and Panitumumab) to account for potential treatment-induced resistance mediated by upstream reactivation of the EGFR pathway [19, 20].”
BackgroundTargeting mutated KRAS in the first‐line therapy
Ijichi, H. (2024) · Clinical and Translational Discovery · doi:10.1002/ctd2.291 · Cited by 1
Pappas, L., Quintanilha, J. C. F., Huang, R. S. P., & Parikh, A. R. (2024) · The Oncologist · doi:10.1093/oncolo/oyae269 · Cited by 1
Yang, P., & Li, Y. (2025) · Investigational New Drugs · doi:10.1007/s10637-025-01514-x · Cited by 1
Chen, J., Wang, J., & Zheng, Q. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1431422 · Cited by 2
ASCO 2025: metastatic colorectal cancer—focus on precision oncology
Schaberl-Moser, R. (2025) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-025-01075-y · Cited by 1
Matteucci, L., Sullo, F. G., Gallio, C., et al. (2024) · Preprints.org · doi:10.20944/preprints202405.0432.v1 · Cited by 1
Davoudi, Z., Dexheimer, T. S., Coussens, N. P., Silvers, T. E., Morris, J., Takebe, N., Doroshow, J. H., & Teicher, B. A. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.11.17.623998 · Cited by 1
Perturbation-guided mapping of colorectal cancer cell states to causal mechanismsPreprint
Hediyeh-zadeh, S., Toh, T. S., Dufva, O., Serra, G., Jakhmola, R., Fourneaux, C., Pinto, G., Fang, Z., Picco, G., Oliver, A. J., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.03.03.708171 · Cited by 1
“These specific inhibitors were selected on the basis of their clinical use for patients with CRC 52,53 and we confirmed the selective sensitivity of organoids to their respective targeted inhibitors ( Extended Data Fig.”
Kano, Y. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27135796
Adaptive Feedback Signaling Through the FAK/SRC Pathway Promotes KRAS G12C Inhibitor Resistance
Udagawa, H., Shibata, Y., Nilsson, M. B., Nishii, K., Robichaux, J. P., Galan-Cobo, A., He, J., Poteete, A., Qian, Y., Molkentine, D., et al. (2026) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2026.103991 · Cited by 1
Gastrointestinal issue: Advances in gastrointestinal oncology
Dekervel, J., & Petrillo, A. (2024) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2024.102437
Colorectal Cancer Highlights from the European Society for Medical Oncology Annual Meeting 2023
Ekmekçiu, I., Nieto, A. E., Scheck, M. K., et al. (2024) · Oncology Research and Treatment · doi:10.1159/000538110
Treatment of Metastatic Colorectal Cancer: Beyond Progression
Güren, A. K., & Köstek, O. (2024) · IntechOpen eBooks · doi:10.5772/intechopen.1004840 · Cited by 1
Zielgerichtete Therapien in der gastrointestinalen Onkologie
Lange, S. (2024) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-2060-2075
Kommentar zu: Divarasib und Adagrasib: sicher und wirksam bei KRAS-G12C-positiven Tumoren?
Roderburg, C., Leyh, C., & Lüdde, T. (2024) · Gastroenterologie up2date · doi:10.1055/a-2207-8578
Fazio, R., Arnold, D., Folprecht, G., Guren, M. G., Koessler, T., Wyrwicz, L. S., & Sclafani, F. (2024) · ESMO Gastrointestinal Oncology · doi:10.1016/j.esmogo.2023.100038
Sotorasib plus Panitumumab bei refraktärem Darmkrebs mit KRAS-G12C-Mutation
Pox, C. P. (2024) · InFo Hämatologie + Onkologie · doi:10.1007/s15004-024-0640-z
An Evolving Landscape: New Therapies for Metastatic Colorectal Cancer
Mo, C., Chadha, B., & Kuang, C. (2024) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2024.08.003 · Cited by 3
Ghosh, S., Fan, F., Powell, R. T., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.09.05.611458
Treatments that Target Cell Communication
Vickers, E. (2024) · Wiley eBooks · doi:10.1002/9781119834090.ch3
Therapeutic Advances in Gastrointestinal Cancers: Immuno-oncology and Beyond
Jalali, S. (2024) · EMJ Oncology · doi:10.33590/emjoncol/pxtf9170
Li, W., & Wang, W. (2024) · Supportive Care in Cancer · doi:10.1007/s00520-024-09024-x · Cited by 1
Palliative Systemtherapie des metastasierten Rektumkarzinoms
Seufferlein, T. T. W., & Ettrich, T. J. (2024) · TumorDiagnostik & Therapie · doi:10.1055/a-2460-8563
Understanding colorectal cancer, screening, and treatment
Ghanta, M. K., Hussain, M. F., Kurumella, S. N. D., Chenchula, S., Kumar, N. N., Malla, M., & Bhaskar, L. V. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-24742-2.00009-5
Gene Editing in ErbB/HER Family-Mediated Cancer Immunology
Yin, L. (2025) · Genetics. · doi:10.5772/intechopen.1008441
Chaperone Directed Heterobifunctional Molecules Circumvent Krasg12c Inhibitor ResistancePreprint
Shimamura, T., Pulido, I., Luan, Q., Pastor-Puente, S., Gunder, L. C., Wang, Y., Ying, C., Li, J., Sun, Y., Dai, Y., et al. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5102509
Therapiekonzepte sowie Prävention/Überwindung von Resistenzen: KRAS/RAS-mutierte Tumoren
Kretzschmar, A. (2025) · Onkologische Welt · doi:10.1055/a-2495-9943
Systemic therapies for localized colon cancer and metastatic colorectal cancer
Platt, J. R. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29048-0.00002-1
Treatment options for KRAS G12C mutated metastatic colorectal cancer
Liberko, M. (2025) · Onkologie · doi:10.36290/xon.2025.008
THSD7A as a novel prognostic factor for colorectal carcinoma
Aktepe, O. H., Kurtulan, O., Dama, P. E., Arslan, A. M., Atağ, E., Üner, M., Korucu, B., Karaoğlu, A., & Yalçın, Ş. (2025) · BMC Gastroenterology · doi:10.1186/s12876-025-03775-5
“Even though treatment with new modalities like monoclonal antibodies, immune checkpoint inhibitors, and targeted therapy has been associated with superior survival outcomes in CRC [6–9], the prognosis of metastatic CRC (mCRC) remains poor, with 5-year survival rate of 14% [10].”
European screening platform for EORTC clinical trials in advanced colorectal cancer ‘SPECTAcolor’
Folprecht, G., Morfouace, M., Collienne, M., Salazar, R., Stein, A., Élez, E., Wagner, D., Arnold, D., Köhne, C. H., Ducreux, M. P., et al. (2025) · ESMO Gastrointestinal Oncology · doi:10.1016/j.esmogo.2025.100168
Research progress on design and discovery of allosteric drugs
Li, R., He, X., Long, L., & Zhang, J. (2025) · Scientia Sinica Chimica · doi:10.1360/ssc-2025-0046
Characteristics and outcome of patients with brain metastases from colorectal cancer
van den Borg, R., Kuhlmann, S. L., Brandsma, D., & Buffart, T. E. (2025) · Neuro-Oncology Practice · doi:10.1093/nop/npaf040 · Cited by 3
“…BRAF -V600E mutation, 31 adagrasib or sotorasib (KRAS inhibitors) with or without anti-EGFR inhibitors for patients with KRAS-G12C mutations, 32,33 HER2 inhibitors for patients with HER2 amplification/overexpression 34 and immune checkpoint inhibitors for MMR-deficient metastatic CRC. 35,36…”
Chang, C., Liang, Y., Lin, B., Chen, K., & Yeh, K. (2025) · JCO Precision Oncology · doi:10.1200/po-24-00609 · Cited by 2
Self-citationLiu, T. F. D., Kazmi, F., Barry, C., Mishra, S. R., Dahal, P. K., Katyal, R., & Shrestha, N. (2025) · Research Square · doi:10.21203/rs.3.rs-7091849/v1
Kolon – Was gibt es Neues beim fortgeschrittenen kolorektalen Karzinom?
Stintzing, S. (2025) · TumorDiagnostik & Therapie · doi:10.1055/a-2547-8391
Consideration of tumor genomics in the management of synchronous colorectal liver metastases
Foster, D. S., & D'Angelica, M. I. (2025) · Surgery Open Science · doi:10.1016/j.sopen.2025.07.009
“Other KRAS G12C inhibitors explored in the colorectal cancer space include Sotorasib and Divarasib [37,38].”
Jensen, L. H. (2025) · The Lancet Oncology · doi:10.1016/s1470-2045(25)00411-5 · Cited by 1
Colorectal cancer treatments show promise
Nierengarten, M. B. (2025) · Cancer · doi:10.1002/cncr.70000
CodeBreaK or code blue? Assessing sotorasib's vital signs in metastatic colorectal cancer
Stevens, S. X., & Gyawali, B. (2025) · Cancer · doi:10.1002/cncr.70056
Mani, H., & Nair, S. (2025) · BMJ Case Reports · doi:10.1136/bcr-2025-266618 · Cited by 1
Treatment Modalities, Targeted Therapies, and Immunotherapy in Metastatic Colorectal Cancer
Karakullukcu, M., & Şenocak, D. (2025) · IntechOpen eBooks · doi:10.5772/intechopen.1012530
Stintzing, S., & Modest, D. P. (2025) · Die Onkologie · doi:10.1007/s00761-025-01830-0
Self-citationWonglhow, J., Wong, H., Michael, M., Heriot, A. G., Guerra, G., Mitchell, C., & Tie, J. (2025) · Cancers · doi:10.3390/cancers17203297 · Cited by 1
“This is notable because KRAS G12C inhibitors such as sotorasib and adagrasib have recently been approved as tumor-agnostic therapies for cancers harboring this mutation [41,42].”
Matsumura, N., & Mandai, M. (2025) · International Journal of Clinical Oncology · doi:10.1007/s10147-025-02901-3
Trovato, G., Schietroma, F., Chiofalo, L., Caira, G., Bologna, A., Sio, D. D., Alfieri, S., Lococo, F., Nachira, D., Margaritora, S., et al. (2025) · The Oncologist · doi:10.1093/oncolo/oyaf384
Self-citationAn Alternative Treatment Effect Measure for Time-to-Event Oncology Randomized Trials
Hutson, A. D., & Yu, H. (2025) · Cancers · doi:10.3390/cancers17233750
Metadata
- Authors
- Fakih, M. G., Salvatore, L., Esaki, T., Modest, D. P., Lopez-Bravo, D. P., Taieb, J., Karamouzis, M. V., Ruiz-Garcia, E., Kim, T.-W., Kuboki, Y., Meriggi, F., Cunningham, D., Yeh, K.-H., Chan, E., Chao, J., Saportas, Y., Tran, Q., Cremolini, C., & Pietrantonio, F.
- Affiliations
- Università Cattolica del Sacro Cuore (IT)
- From Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte (M.G.F.), and Amgen, Thousand Oaks (E.C., J.C., Y.S., Q.T.) — both in California; Oncologia Medica, Università Cattolica del Sacro Cuore, and Oncologia Medica, Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome (L.S.), the Oncology Department, Fondazione Poliambulanza Istituto Ospedaliero, Brescia (F.M.), the Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa (C.C.), and the Medical Oncology Department, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale dei Tumori, Milan (F.P.) — all in Italy; the Department of Gastrointestinal and Medical Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka (T.E.), and the Experimental Therapeutics and GI Oncology Department, National Cancer Center Hospital East, Kashiwa (Y.K.) — both in Japan; the Medicine Department of Hemato...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-12-07
- Volume
- 389
- Issue
- 23
- Pages
- 2125-2139
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4387859726
- Semantic Scholar
- 775955729cc149c0cdcaed25ee8100657413b921
- Cited by
- 398
- References
- 37
- Citations by year
- 2026: 127 · 2025: 143 · 2024: 121 · 2023: 7
- FWCI
- 48.32
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- Funders
- Amgen (NA)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- sotorasib, panitumumab, KRAS G12C mutation, metastatic colorectal cancer, EGFR inhibition, KRAS G12C inhibitors, combination therapy, progression-free survival, overall survival, objective response, trifluridine/tipiracil, regorafenib, dose comparison, refractory cancer, targeted therapy
- MeSH terms
- Antineoplastic Agents, Immunological, Panitumumab, Immune Checkpoint Inhibitors, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Humans, Mutation, Phenylurea Compounds, Piperazines, Pyridines, Pyrimidines, Pyrrolidines, Thymine, Trifluridine, Colorectal Neoplasms, Proto-Oncogene Proteins p21(ras), Antibodies, Monoclonal, Humanized, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.